Literature DB >> 10361107

Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT.

A Cohen1, A Rovelli, B Bakker, C Uderzo, M T van Lint, H Esperou, A Gaiero, A D Leiper, R Dopfer, J Y Cahn, F Merlo, H J Kolb, G Socié.   

Abstract

Few data are available on the long-term effect of bone marrow transplantation (BMT) on growth. This study examines those factors that play a role in the final height outcome of patients who underwent BMT during childhood. Data on 181 of 230 patients with aplastic anemia, leukemias, and lymphomas who had BMT before puberty (mean age, 9.8 +/- 2.6 years) and who had reached their final height were analyzed. An overall decrease in final height standard deviation score (SDS) value was found compared with the height at BMT (P < 10(7)) and with the genetic height (P < 10(7)). Girls did better than boys, and the younger in age the person was at time of BMT, the greater the loss in height. Previous cranial irradiation + single-dose total body irradiation (TBI) caused the greatest negative effect on final height achievement (P < 10(4)). Fractionation of TBI reduces this effect significantly and conditioning with busulfan and cyclophosphamide seems to eliminate it. The type of transplantation, graft-versus-host disease, growth hormone, or steroid treatment did not influence final height. Irradiation, male gender and young age at BMT were found to be major factors for long-term height loss. Nevertheless, the majority of patients (140/181) have reached adult height within the normal range of the general population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361107

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

2.  Late effects of myeloablative bone marrow transplantation (BMT) in sickle cell disease (SCD).

Authors:  Courtney D Fitzhugh; Shira Perl; Matthew M Hsieh
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

3.  Late toxicity in children undergoing hematopoietic stem cell transplantation with TBI-containing conditioning regimens for hematological malignancies.

Authors:  Umberto Ricardi; Andrea Riccardo Filippi; Eleonora Biasin; Patrizia Ciammella; Angela Botticella; Pierfrancesco Franco; Andrea Corrias; Elena Vassallo; Riccardo Ragona; Franca Fagioli
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

4.  Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report.

Authors:  Eric J Chow; Wei Liu; Kumar Srivastava; Wendy M Leisenring; Robert J Hayashi; Charles A Sklar; Marilyn Stovall; Leslie L Robison; K Scott Baker
Journal:  Pediatr Blood Cancer       Date:  2012-05-24       Impact factor: 3.167

5.  Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation.

Authors:  Hiroto Inaba; Jie Yang; Sue C Kaste; Christine M Hartford; Megan S Motosue; Wassim Chemaitilly; Brandon M Triplett; David R Shook; Ching-Hon Pui; Wing Leung
Journal:  J Clin Oncol       Date:  2012-10-01       Impact factor: 44.544

6.  Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.

Authors:  Sakurako Izaki; Hiroaki Goto; Kumiko Okuda; Motoi Matsuda; Yuka Watanabe; Kenichirou Fujioka; Noriyuki Hanzawa; Hiroko Sumita; Hiroyuki Takahashi; Shoko Goto; Sumio Kai; Haruyuki Sekiguchi; Tetsunori Funabiki; Hideki Sasaki; Koichiro Ikuta; Shumpei Yokota
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

7.  Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters.

Authors:  D Bresters; A Lawitschka; C Cugno; U Pötschger; A Dalissier; G Michel; K Vettenranta; M Sundin; A Al-Seraihy; M Faraci; P Sedlacek; A B Versluys; A Jenkins; P Lutz; B Gibson; A Leiper; M A Diaz; P J Shaw; R Skinner; T A O'Brien; N Salooja; P Bader; C Peters
Journal:  Bone Marrow Transplant       Date:  2016-06-27       Impact factor: 5.483

8.  SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID.

Authors:  Catharina Schuetz; Benedicte Neven; Christopher C Dvorak; Sandrine Leroy; Markus J Ege; Ulrich Pannicke; Klaus Schwarz; Ansgar S Schulz; Manfred Hoenig; Monika Sparber-Sauer; Susanne A Gatz; Christian Denzer; Stephane Blanche; Despina Moshous; Capucine Picard; Biljana N Horn; Jean-Pierre de Villartay; Marina Cavazzana; Klaus-Michael Debatin; Wilhelm Friedrich; Alain Fischer; Morton J Cowan
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

9.  Endocrine complications after hematopoietic stem cell transplantation during childhood and adolescence.

Authors:  Min Ho Jung; Kyoung Soon Cho; Jae Wook Lee; Nak Gyun Chung; Bin Cho; Byung Kyu Suh; Hack Ki Kim; Byung Churl Lee
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

10.  Growth after hematopoietic stem cell transplantation in children with acute myeloid leukemia.

Authors:  Seung Joon Chung; Seung Wan Park; Min Kyoung Kim; Min Jae Kang; Young Ah Lee; Seong Yong Lee; Choong Ho Shin; Sei Won Yang; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.